SELLAS Life Sciences Group announced final clinical and immunobiological data from the Phase 1/2 clinical trial of galinpepimut-S, GPS, in combination with pembrolizumab in Wilms’ tumor-1-positive platinum-resistant ovarian cancer. Results are being presented in an e-poster session by Roisin E. O’Cearbhaill, M.D., Research Director, Gynecologic Medical Oncology Service; Clinical Director, Solid Tumor, Cellular Therapy Service; and Associate Attending Physician at Memorial Sloan Kettering Cancer Center, New York, NY, at the 2023 International Gynecologic Cancer Society Annual Global Meeting taking place November 5-7, 2023, in Seoul, South Korea.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SLS:
- SELLAS Life Sciences Presents Positive Key Immunobiological and Clinical Data from Phase 1/2 Trial of Galinpepimut-S (GPS) in Combination with Keytruda® in WT1+ Platinum-Resistant Advanced Ovarian Cancer at the International Gynecologic Cancer Society 2023 Annual Global Meeting
- Sellas Life Sciences sells 3.65M shares at $1.0952 in registered direct offering
- SELLAS Life Sciences Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- SELLAS Life Sciences Receives Fast Track Designation from FDA for SLS009 for Treatment of Relapsed/Refractory Peripheral T-cell Lymphomas
- Sellas Life Sciences receives Fast Track designation for SLS009